Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 693

1.

Bone-targeted therapy in castration-resistant prostate cancer: where do we stand?

Gómez Rivas J, Carrion DM, Alvarez-Maestro M, Cathelineau X, Sanchez-Salas R, Di Lorenzo G, Di Maio M, Paul A, Martinez-Piñeiro L, Sartor O, Saad F, Debruyne F.

Minerva Urol Nefrol. 2019 Oct;71(5):445-456. doi: 10.23736/S0393-2249.19.03420-9. Epub 2019 Jul 25.

2.

Automated Bone Scan Index as an Imaging Biomarker to Predict Overall Survival in the Zometa European Study/SPCG11.

Reza M, Wirth M, Tammela T, Cicalese V, Veiga FG, Mulders P, Miller K, Tubaro A, Debruyne F, Patel A, Caris C, Witjes W, Thorsson O, Wollmer P, Edenbrandt L, Ohlsson M, Trägårdh E, Bjartell A.

Eur Urol Oncol. 2019 Jun 8. pii: S2588-9311(19)30069-0. doi: 10.1016/j.euo.2019.05.002. [Epub ahead of print]

PMID:
31186177
3.

Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study.

van der Leest M, Cornel E, Israël B, Hendriks R, Padhani AR, Hoogenboom M, Zamecnik P, Bakker D, Setiasti AY, Veltman J, van den Hout H, van der Lelij H, van Oort I, Klaver S, Debruyne F, Sedelaar M, Hannink G, Rovers M, Hulsbergen-van de Kaa C, Barentsz JO.

Eur Urol. 2019 Apr;75(4):570-578. doi: 10.1016/j.eururo.2018.11.023. Epub 2018 Nov 23.

4.

Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations.

Crawford ED, Heidenreich A, Lawrentschuk N, Tombal B, Pompeo ACL, Mendoza-Valdes A, Miller K, Debruyne FMJ, Klotz L.

Prostate Cancer Prostatic Dis. 2019 Mar;22(1):24-38. doi: 10.1038/s41391-018-0079-0. Epub 2018 Aug 21. Review.

5.

A Dose-Escalating Study With the Fetal Estrogen Estetrol in Healthy Men.

Coelingh Bennink HJT, Zimmerman Y, Verhoeven C, Dutman AE, Mensinga T, Kluft C, Reisman Y, Debruyne FMJ.

J Clin Endocrinol Metab. 2018 Sep 1;103(9):3239-3249. doi: 10.1210/jc.2018-00147.

PMID:
29931320
6.

Quality of Life and Sexual Function Benefits of Long-Term Testosterone Treatment: Longitudinal Results From the Registry of Hypogonadism in Men (RHYME).

Rosen RC, Wu F, Behre HM, Porst H, Meuleman EJH, Maggi M, Romero-Otero J, Martinez-Salamanca JI, Jones TH, Debruyne FMJ, Kurth KH, Hackett GI, Quinton R, Stroberg P, Reisman Y, Pescatori ES, Morales A, Bassas L, Cruz N, Cunningham GR, Wheaton OA; RHYME Investigators.

J Sex Med. 2017 Sep;14(9):1104-1115. doi: 10.1016/j.jsxm.2017.07.004. Epub 2017 Aug 7.

PMID:
28781213
7.

Precision surgery and genitourinary cancers.

Autorino R, Porpiglia F, Dasgupta P, Rassweiler J, Catto JW, Hampton LJ, Lima E, Mirone V, Derweesh IH, Debruyne FMJ.

Eur J Surg Oncol. 2017 May;43(5):893-908. doi: 10.1016/j.ejso.2017.02.005. Epub 2017 Feb 20. Review.

PMID:
28254473
8.

European Association of Urology Position Statement on the Role of the Urologist in the Management of Male Hypogonadism and Testosterone Therapy.

Mirone V, Debruyne F, Dohle G, Salonia A, Sofikitis N, Verze P, Fode M, Chapple C; URO-TRAM working group.

Eur Urol. 2017 Aug;72(2):164-167. doi: 10.1016/j.eururo.2017.02.022. Epub 2017 Feb 27.

PMID:
28249799
9.

Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial.

Azzouzi AR, Vincendeau S, Barret E, Cicco A, Kleinclauss F, van der Poel HG, Stief CG, Rassweiler J, Salomon G, Solsona E, Alcaraz A, Tammela TT, Rosario DJ, Gomez-Veiga F, Ahlgren G, Benzaghou F, Gaillac B, Amzal B, Debruyne FM, Fromont G, Gratzke C, Emberton M; PCM301 Study Group.

Lancet Oncol. 2017 Feb;18(2):181-191. doi: 10.1016/S1470-2045(16)30661-1. Epub 2016 Dec 20.

10.

Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men.

Debruyne FM, Behre HM, Roehrborn CG, Maggi M, Wu FC, Schröder FH, Jones TH, Porst H, Hackett G, Wheaton OA, Martin-Morales A, Meuleman E, Cunningham GR, Divan HA, Rosen RC; RHYME Investigators.

BJU Int. 2017 Feb;119(2):216-224. doi: 10.1111/bju.13578. Epub 2016 Aug 14.

11.

Predictive factors of speech understanding in adults with cochlear implants.

Dierickx C, Jacquemin L, Boon E, Dierckx A, Debruyne F, Wouters J, Desloovere C, Verhaert N.

B-ENT. 2016;12(3):219-226.

PMID:
29727127
12.

Otosclerosis: Shift in bone conduction after stapedotomy.

Sabbe A, Verhaert N, Joossen I, Lammens A, Debruyne F.

B-ENT. 2015;11(3):183-9.

PMID:
26601550
13.

Legends in urology.

Debruyne FM.

Can J Urol. 2015 Apr;22(2):7678-80. No abstract available.

14.

Incidence of multiglandular disease in sporadic primary hyperparathyroidism.

Vandenbulcke O, Delaere P, Vander Poorten V, Debruyne F.

B-ENT. 2014;10(1):1-6.

PMID:
24765822
15.

Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS).

Wirth M, Tammela T, Cicalese V, Gomez Veiga F, Delaere K, Miller K, Tubaro A, Schulze M, Debruyne F, Huland H, Patel A, Lecouvet F, Caris C, Witjes W.

Eur Urol. 2015 Mar;67(3):482-91. doi: 10.1016/j.eururo.2014.02.014. Epub 2014 Feb 20.

PMID:
24630685
16.

Fifteen years of early hearing screening in Flanders: impact on language and education.

Desloovere C, Verhaert N, Van Kerschaver E, Debruyne F.

B-ENT. 2013;Suppl 21:81-90.

PMID:
24383226
17.

Aetiology of congenital hearing loss: a cohort review of 569 subjects.

Lammens F, Verhaert N, Devriendt K, Debruyne F, Desloovere C.

Int J Pediatr Otorhinolaryngol. 2013 Sep;77(9):1385-91. doi: 10.1016/j.ijporl.2013.06.002. Epub 2013 Jul 5. Review.

PMID:
23835162
18.

Noise exposure of care providers during otosurgical procedures.

Verhaert N, Moyaert N, Godderis L, Debruyne F, Desloovere C, Luts H.

B-ENT. 2013;9(1):3-8.

PMID:
23641584
19.

Tonsillectomy compared to acute tonsillitis in children: a comparison study of societal costs.

Leupe P, Hox V, Debruyne F, Schrooten W, Claes NV, Lemkens N, Lemkens P.

B-ENT. 2012;8(2):103-11.

PMID:
22896929
20.
21.

Role of testosterone in managing advanced prostate cancer.

Rove KO, Debruyne FM, Djavan B, Gomella LG, Koul HK, Lucia MS, Petrylak DP, Shore ND, Stone NN, Crawford ED.

Urology. 2012 Oct;80(4):754-62. doi: 10.1016/j.urology.2012.05.006. Epub 2012 Jul 13. Review.

PMID:
22795376
22.

Prevalence of risk factors for sensorineural hearing loss in NICU newborns.

Speleman K, Kneepkens K, Vandendriessche K, Debruyne F, Desloovere C.

B-ENT. 2012;8(1):1-6.

PMID:
22545383
23.

Effect of adenotonsillectomy on the use of respiratory medication.

Piessens P, Hens G, Lemkens N, Schrooten W, Debruyne F, Lemkens P.

Int J Pediatr Otorhinolaryngol. 2012 Jun;76(6):906-10. doi: 10.1016/j.ijporl.2012.02.069. Epub 2012 Mar 27.

PMID:
22456167
24.

Pre-operative imaging in primary hyperparathyroidism with ultrasonography and sestamibi scintigraphy.

Leupe PK, Delaere PR, Vander Poorten VL, Debruyne F.

B-ENT. 2011;7(3):173-80.

PMID:
22026137
25.

Time to onset of action of vardenafil: a retrospective analysis of the pivotal trials for the orodispersible and film-coated tablet formulations.

Debruyne FM, Gittelman M, Sperling H, Börner M, Beneke M.

J Sex Med. 2011 Oct;8(10):2912-23. doi: 10.1111/j.1743-6109.2011.02462.x. Epub 2011 Aug 30.

PMID:
21883954
26.

Improvement in sexual quality of life of the female partner following vardenafil treatment of men with erectile dysfunction: a randomized, double-blind, placebo-controlled study.

Martín-Morales A, Graziottin A, Jaoudé GB, Debruyne F, Buvat J, Beneke M, Neuser D.

J Sex Med. 2011 Oct;8(10):2831-40. doi: 10.1111/j.1743-6109.2011.02352.x. Epub 2011 Jun 16.

PMID:
21679304
27.

Antibiotic use and doctor visits are reduced after adenotonsillectomy.

Lemkens N, Lemkens P, Egondi TW, Schrooten W, Jorissen M, Mertens R, de Raeve G, Preal R, Debruyne F.

B-ENT. 2010;6(4):239-43.

PMID:
21302684
28.

Dose-ranging study of the luteinizing hormone-releasing hormone receptor antagonist cetrorelix pamoate in the treatment of patients with symptomatic benign prostatic hyperplasia.

Debruyne F, Tzvetkov M, Altarac S, Geavlete PA.

Urology. 2010 Oct;76(4):927-33. doi: 10.1016/j.urology.2009.09.077.

PMID:
20932411
29.

Medical students' exposure to urology in European schools: the European Association of Urology proposals for a convergence programme.

Navarrete RV, Le Duc A, Ackermann R, Boccon-Gibod L, Debruyne F, Ekman P, Jonas U, Abrahamsson PA, Artibani W, Chapple C, Wirth M.

Eur Urol. 2010 Oct;58(4):528-31. doi: 10.1016/j.eururo.2010.07.027. Epub 2010 Aug 2. No abstract available.

PMID:
20728268
30.

The role of nocturia in the quality of life of men with lower urinary tract symptoms.

Van Dijk MM, Wijkstra H, Debruyne FM, De La Rosette JJ, Michel MC.

BJU Int. 2010 Apr;105(8):1141-6.

31.

The POTENT I randomized trial: efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction.

Sperling H, Debruyne F, Boermans A, Beneke M, Ulbrich E, Ewald S.

J Sex Med. 2010 Apr;7(4 Pt 1):1497-507. doi: 10.1111/j.1743-6109.2010.01806.x. Epub 2010 Mar 3.

PMID:
20233275
32.

Migraine presenting as chronic facial pain.

Debruyne F, Herroelen L.

Acta Neurol Belg. 2009 Sep;109(3):235-7.

PMID:
19902820
33.

Paroxysmal nonkinesigenic dyskinesias due to recurrent hypoglycemia caused by an insulinoma.

Debruyne F, Van Paesschen W, Van Eyken P, Bex M, Vandenberghe W.

Mov Disord. 2009 Feb 15;24(3):460-1. doi: 10.1002/mds.22386. No abstract available.

PMID:
19235926
34.

Neurodegenerative Parkinsonism and progressive external ophthalmoplegia with a Twinkle mutation.

Vandenberghe W, Van Laere K, Debruyne F, Van Broeckhoven C, Van Goethem G.

Mov Disord. 2009 Jan 30;24(2):308-9. doi: 10.1002/mds.22198. No abstract available.

PMID:
18973250
35.

Placebo-controlled dose-ranging phase 2 study of subcutaneously administered LHRH antagonist cetrorelix in patients with symptomatic benign prostatic hyperplasia.

Debruyne F, Gres AA, Arustamov DL.

Eur Urol. 2008 Jul;54(1):170-7. doi: 10.1016/j.eururo.2008.03.069. Epub 2008 Apr 1.

PMID:
18417275
36.

Re-operation for secondary hyperparathyroidism.

Debruyne F, Geuens G, Vander Poorten V, Delaere P.

J Laryngol Otol. 2008 Sep;122(9):942-7. Epub 2007 Nov 30.

PMID:
18047758
37.

Parathyroidectomy after successful kidney transplantation: a single centre study.

Evenepoel P, Claes K, Kuypers DR, Debruyne F, Vanrenterghem Y.

Nephrol Dial Transplant. 2007 Jun;22(6):1730-7. Epub 2007 Mar 19. Review.

PMID:
17371780
38.

The middle ear of cleft palate patients in their early teens: a literature study and preliminary file study.

Timmermans K, Vander Poorten V, Desloovere C, Debruyne F.

B-ENT. 2006;2 Suppl 4:95-101. Review.

PMID:
17366853
39.

Abarelix for injectable suspension: first-in-class gonadotropin-releasing hormone antagonist for prostate cancer.

Debruyne F, Bhat G, Garnick MB.

Future Oncol. 2006 Dec;2(6):677-96. Review.

PMID:
17155895
40.

Subspecialty certification in urology: a European perspective.

Debruyne FM.

Nat Clin Pract Urol. 2006 Dec;3(12):625. No abstract available.

PMID:
17149375
41.

Levothyroxine replacement therapy after thyroid surgery.

Verhaert N, Vander Poorten V, Delaere P, Bex M, Debruyne F.

B-ENT. 2006;2(3):129-33.

PMID:
17067083
42.
43.

My congratulations to the German Society of Urology!

Debruyne FM.

Urologe A. 2006 Sep;45 Suppl 4:35-6. No abstract available.

PMID:
16955321
44.

Medical management of BPH: the debate continues.

Debruyne FM.

Eur Urol. 2006 Sep;50(3):416-7. Epub 2006 Jul 5. No abstract available.

PMID:
16860460
45.

PSA velocity in conservatively managed BPH: can it predict the need for BPH-related invasive therapy?

Mochtar CA, Kiemeney LA, Laguna MP, Debruyne FM, de la Rosette JJ.

Prostate. 2006 Sep 15;66(13):1407-12.

PMID:
16741919
46.

Implant-Driven Tibial Nerve Stimulation in the Treatment of Refractory Overactive Bladder Syndrome: 12-Month Follow-up.

van der Pal F, van Balken MR, Heesakkers JP, Debruyne FM, Bemelmans BL.

Neuromodulation. 2006 Apr;9(2):163-71. doi: 10.1111/j.1525-1403.2006.00056.x.

PMID:
22151641
47.

Intravesical chemotherapy for superficial bladder cancer.

Witjes JA, Debruyne FM.

Nat Clin Pract Urol. 2004 Dec;1(2):56-7. No abstract available.

PMID:
16474497
48.

Percutaneous tibial nerve stimulation in the treatment of refractory overactive bladder syndrome: is maintenance treatment necessary?

van der Pal F, van Balken MR, Heesakkers JP, Debruyne FM, Bemelmans BL.

BJU Int. 2006 Mar;97(3):547-50.

49.

Brown tumour: presenting symptom of primary hyperparathyroidism.

Grulois V, Buysschaert I, Schoenaers J, Debruyne F, Delaere P, Vander Poorten V.

B-ENT. 2005;1(4):191-5.

PMID:
16429752
50.

Post-void residual urine volume is not a good predictor of the need for invasive therapy among patients with benign prostatic hyperplasia.

Mochtar CA, Kiemeney LA, van Riemsdijk MM, Laguna MP, Debruyne FM, de la Rosette JJ.

J Urol. 2006 Jan;175(1):213-6.

PMID:
16406914

Supplemental Content

Loading ...
Support Center